This cocaine analog binds with high affinity to the dopamine transporter (Ki = 30 nM) and blocks re-uptake of dopamine. However, it is a weak psychomotor stimulant and does not substitute for cocaine in addicted rats.
|Storage||Store at RT|
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
All Tocris products are intended for laboratory research use only.
|Solvent||Max Conc. mg/mL||Max Conc. mM|
Preparing Stock Solutions
The following data is based on the product molecular weight 378.34. Batch specific molecular weights may vary from batch to batch due to solvent of hydration, which will affect the solvent volumes required to prepare stock solutions.
|Concentration / Solvent Volume / Mass||1 mg||5 mg||10 mg|
|1 mM||2.64 mL||13.22 mL||26.43 mL|
|5 mM||0.53 mL||2.64 mL||5.29 mL|
|10 mM||0.26 mL||1.32 mL||2.64 mL|
|50 mM||0.05 mL||0.26 mL||0.53 mL|
References are publications that support the products' biological activity.
Newman et al (1994) Novel 3α-(diphenylmethoxy)tropane analogs: potent dopamine uptake inhibitors without cocaine-like behavioural profiles. J.Med.Chem. 37 2258 PMID: 8057273
Newman et al (1995) Novel 4'-substituted and 4'4"-disubstituted 3α-(diphenylmethoxy)tropane analogs as potent and selective dopamine uptake inhibitors. J.Med.Chem. 38 3933 PMID: 7562926
If you know of a relevant reference for 3-CPMT, please let us know.
View Related Products by Product Action
Keywords: 3-CPMT, supplier, Dopamine, reuptake, inhibitors, inhibits, DAT, Transporters, Monoamine, Neurotransmitter, Dopamine, Transporters, Dopamine, Transporters, Tocris Bioscience
Citations for 3-CPMT
Citations are publications that use Tocris products.
Currently there are no citations for 3-CPMT. Do you know of a great paper that uses 3-CPMT from Tocris? If so please let us know.
Average Rating:(Based on 0 Reviews)
Literature in this Area
Dopamine Receptors Scientific Review
Written by Phillip Strange and revised by Kim Neve in 2013, this review summarizes the history of the dopamine receptors and provides an overview of individual receptor subtype properties, their distribution and identifies ligands which act at each receptor subtype. Compounds available from Tocris are listed.
The key feature of drug addiction is the inability to stop using a drug despite clear evidence of harm. This poster describes the brain circuits associated with addiction, and provides an overview of the main classes of addictive drugs and the neurotransmitter systems that they target.
Parkinson's disease (PD) causes chronic disability and is the second most common neurodegenerative condition. This poster outlines the neurobiology of the disease, as well as highlighting current therapeutic treatments for symptomatic PD, and emerging therapeutic strategies to delay PD onset and progression.